Literature DB >> 2936823

Membrane-associated IL 1-like activity on rat dendritic cells.

L M Nagelkerken, P J van Breda Vriesman.   

Abstract

The secretion of interleukin 1 (IL 1) by rat dendritic cells (DC) was studied in relation to their ability to induce the production of interleukin 2 (IL 2) and to induce IL 2 responsiveness. IL 1 (or IL 1-like activity) was measured by its capacity to enhance IL 2 production by EL4 cells. In contrast to peritoneal exudate cells (PEC) or splenic adherent cells, DC from thoracic duct lymph (TD-DC) or from spleen did not secrete detectable amounts of IL 1 on stimulation with LPS/Silica. However, TD-DC and splenic DC were able to enhance IL 2 production by EL4 cells directly, and were only two times less effective than PEC. By preventing cell-to-cell contact between stimulator cells and EL4 cells, it was demonstrated that most of the IL 2-inducing activity of TD-DC and PEC was associated with the cell membrane. Treatment with 1% paraformaldehyde (PFA) to abolish metabolic activity resulted in a 50% decrease (or inactivation) of IL 2-inducing activity of TD-DC in the EL4 assay. Moreover, UVB-irradiation (300 mJ/cm2) of TD-DC, which has been described to inhibit the release of IL 1 by macrophages, caused a 70% decrease in IL 2-inducing activity. In a primary allogeneic mixed leukocyte reaction, neither PFA-treated TD-DC nor UV-irradiated TD-DC were able to induce T cell proliferation or IL 2 production. The cells were, however, able to induce IL 2 responsiveness, i.e., T cell proliferation in the presence of excess human recombinant IL 2. The finding that IL 1 enhanced T cell responses to PFA-treated or UV-irradiated TD-DC in the absence and in the presence of excess IL 2 indicates that loss of stimulatory activity of TD-DC may be due in part to loss or inactivation of IL 1. These results suggest that membrane-associated structures, that are identical to or mimic IL 1, are involved in the activation of T cells by DC.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2936823

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Antigen presenting cells.

Authors:  D L Hamilos
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

Review 2.  Dendritic cells in rheumatoid inflammation.

Authors:  K Waalen; O Førre; J B Natvig
Journal:  Springer Semin Immunopathol       Date:  1988

Review 3.  The role of tumor necrosis factor and interleukin 1 in the immunoinflammatory response.

Authors:  J W Larrick; S L Kunkel
Journal:  Pharm Res       Date:  1988-03       Impact factor: 4.200

4.  Accessory cell functions of dendritic cells and macrophages in the thymic T-cell response to Con A.

Authors:  Y Hirayama; K Inaba; S Komatsubara; K Yoshida; J Kawai; K Naito; S Muramatsu
Journal:  Immunology       Date:  1987-11       Impact factor: 7.397

5.  Interleukin-1 alpha production during Rickettsia rickettsii infection of cultured endothelial cells: potential role in autocrine cell stimulation.

Authors:  L A Sporn; V J Marder
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

6.  Differential regulation of soluble interleukin 1 release and membrane expression by pharmacologic agents.

Authors:  S R Brandwein
Journal:  Agents Actions       Date:  1990-06

7.  Brucella abortus regulates bovine macrophage-T-cell interaction by major histocompatibility complex class II and interleukin-1 expression.

Authors:  G A Splitter; K M Everlith
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

8.  Human dendritic cells stimulate allogeneic T cells in the absence of IL-1.

Authors:  J L McKenzie; T C Prickett; D N Hart
Journal:  Immunology       Date:  1989-07       Impact factor: 7.397

9.  Interleukin 1 beta is localized in the cytoplasmic ground substance but is largely absent from the Golgi apparatus and plasma membranes of stimulated human monocytes.

Authors:  I I Singer; S Scott; G L Hall; G Limjuco; J Chin; J A Schmidt
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.